More recently, Tam and colleagues developed another anti-TNFR2 antibody, Y2, which binds to the receptor outside of the TNF-binding site and accelerates the anti-tumor activity as Fc-dependent agonism of conventional T cells [120]. Here, TNFRSF1B is linked to neoplasm.